Plus, how two little-known boutique banks became Trump family favourites and inside the quant funds that are dominating London
It’s hard to think of a better candidate for a demerger than the £16bn Associated British Foods
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history
US judge declines to intervene in fray because process ‘is creating value for Metsera stockholders’
Plus, inside the super secretive intelligence firm Black Cube and Pfizer takes no prisoners in its fight to buy Metsera
Building up financial exposure to a business you don’t control can be risky, but buying minority stakes does offer advantages
Hong Kong-based private equity group to own up to 60% of new joint venture valued at $4bn
Investment in project off UK’s coast boosts Danish developer battling rising costs and political challenges
Merger would create consumer goods business with $32bn a year in sales
Novo and Metsera deny Pfizer’s arguments
$49bn tie-up comes on frantic day of mergers and acquisitions across corporate America
SM Energy and Civitas Resources announce all-stock ‘strategic combination’
Executives at accounting network have spoken to bankers and lawyers to scope out possible private capital deals
Dealmaker chief is clinging to his ambition to build a pan-European banking powerhouse despite M&A roadblocks
Average time to complete a deal has fallen to four months
Insurers are engaged in an annuity-style policies land grab as they seek growth quickly
FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk
Chief executives of the world’s big companies have decided to get back in the deal making game
Final agreement would mark end of French telecoms company’s joint venture with private equity group Lorca
Plus, how a little-known Utah lender became First Brands’ biggest creditor and Novo Nordisk gatecrashes Pfizer’s latest deal
Mubadala Capital-backed group to become latest private capital player in life insurance sector
Buyout bosses intend to contest any attempt by competition watchdog to disqualify them as directors of British companies
Bid for drugmaker Metsera is unusually aggressive in terms of price, timing and structure
Swedish buyout group holds preliminary talks with owners Permira and Blackstone
Deal’s collapse could hurt CoreWeave plans to meet growth plans that have driven soaring stock price
